ArticleMolecular therapy. Oncology2025

Preclinical development and selection of nanobody-based CAR-T cells targeting HER2-positive solid tumors.

Fien Meeus et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.